Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment

Neurology

Volumn 70, Issue 13 PART 2, 2008, Pages 1134-1140

  Polman, Chris H ^a   Reingold, S C ^b,c   Barkhof, F ^a   Calabresi, P A ^d   Clanet, M ^e   Cohen, J A ^f   Cutter, G R ^g   Freedman, M S ^h   Kappos, L ⁱ   Lublin, F D ^j   McFarland, H F ^k   Metz, L M ^l   Miller, A E ^j   Montalban, X ^m   O'Connor, P W ⁿ   Panitch, H ^o   Richert, J R ^c   Petkau, J ^p   Schwid, S R ^q   Sormani, M P ^r,s   Thompson, A J ^t   Weinshenker, B G ^u   Wolinsky, J S ^v   more..

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Scientific and Clinical Review Associates LLC   (United States)

^c National Multiple Sclerosis Society   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

^e CHU PURPAN   (France)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h UNIVERSITY OF OTTAWA   (Canada)

ⁱ UNIVERSITY OF BASEL   (Switzerland)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^k NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^l UNIVERSITY OF CALGARY   (Canada)

^m HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁿ ST MICHAEL'S HOSPITAL   (Canada)

^o UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^p UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^q UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^r UNIVERSITY OF GENOA   (Italy)

^s SAN RAFFAELE HOSPITAL   (Italy)

^t NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^u Mayo Clinic   (United States)

^v UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

DRUG INDUSTRY; MEDICAL ETHICS; MEDICAL SOCIETY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW;

EID: 41549132629     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000306410.84794.4d     Document Type: Article

References (45)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 1993;43:655-661.
2. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276.
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
4. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
5. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double blind, randomised, multicenter trial. Lancet 2002;360:2018-2025.
6. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
7. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-β-treated relapsing multiple sclerosis. Ann Neurol 2007;61:300-306.
8. Brown JR, Beebe GW, Kurtzke JF, et al. The design of clinical studies to assess therapeutic efficacy in multiple sclerosis. Neurology 1979;29:3-23.
9. Weiner HL, Ellison GW. A working protocol to be used as a guideline for trials in multiple sclerosis. Arch Neurol 1983;40:704-710.
10. McFarland HF, Reingold SC. The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic era. Mult Scler 2005;11:669-676.
11. World Medical Association. Declaration of Helsinki. Available at: http://www.wma.net/e/policy/b3.htm. Accessed September 12, 2007.
12. Lie RK, Emanuel E, Grady C, Wendler D. The standard of care debate: The Declaration of Helsinki versus the international consensus opinion. J Med Ethics 2004;30:190-192.
13. Lewis JA, Jonsson B, Kreutz G, et al. Placebo-controlled trials and the Declaration of Helsinki. Lancet 2002;359:1337-1340.
14. Ellenberg SS. Scientific and ethical issues in the use of placebo and active controls in clinical trials. J Bone Miner Res 2003;18:1121-1124.
15. Health Canada/Canadian Institutes of Health Research. Final report of the national placebo working committee on the appropriate use of placebos in clinical trials in Canada. 2004. Available at: http://www.irsc.gc.ca/e/25139. html. Accessed September 12, 2007.
16. Brody BA, McCullough LB, Sharp RR. Consensus and controversy in clinical research ethics. JAMA 2005;294:1411-1414.
17. Lublin FD, Reingold SC. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. Ann Neurol 2001;49:677-681.
18. Miller AE. Ethical issues in multiple sclerosis clinical trials. Mult Scler 2005;11:97-98.
19. Miller AE. Ethical considerations in multiple sclerosis clinical trials. In: Cohen JA, Rudick RA, eds. Multiple Sclerosis Therapeutics, 3rd ed. London, UK: Informa Healthcare, 2007:343-356.
20. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000:343;898-904.
21. Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004;264:1489-1496.
22. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinical definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-1249.
23. Freedman MS, Polman CH, Kappos L, et al. Betaseron® in newly emerging multiple sclerosis (BENEFIT): effects of immediate vs. early onset of interferon beta-1b treatment. Neurology 2007;68(suppl 1):A85. Abstract.
24. National Multiple Sclerosis Society. Clinical trials. Available at: http://www.nationalmssociety.org/site/PageServer?pagename= HOM_RES_clinical_trials. Accessed September 12, 2007.
25. Multiple Sclerosis International Federation. Clinical trials. Available at: http://www.msif.org/en/research/clinical_trials/index.html. Accessed September 12, 2007.
26. Joffee S, Cook EF, Cleary PD, Clark JW, Weeks JC. Quality of informed consent in cancer clinical trials: a cross-sectional survey. Lancet 2001;358:1772-1777.
27. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528-1532.
28. Macklin R. After Helsinki: Unresolved issues in international research. Kennedy Inst Ethics J 2001;11:17-26.
29. Shapiro HT, Meslin EM. Ethical issues in the design and conduct of clinical research in developing countries. N Engl J Med 2001;345:139-142.
30. Nuffield Council on Bioethics. The ethical relevance of research related to health care in developing countries. 2002. Available at: www. nuffieldbioethics.org/go/ourwork/developingcountries/publication_309.html. Accessed September 12, 2007.
31. Levine RJ, Carpenter WT, Appelbaum PS. Clarifying standards for using placebos. Science 2002;18:1154-1159.
32. Vogel G. Ethics group gives qualified nod to placebos. Science 2003;299:995-996.
33. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl Med 2003;348:15-23.
34. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-1140.
35. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-953.
36. Rudick RA, Cutter GC. Interferon-β for multiple sclerosis: Long-term benefit? Ann Neurol 2007;61:283-285.
37. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-397.
38. Tullman MJ, Lublin FD. Combination therapy in multiple sclerosis. Curr Neurol Neurosci Rep 2005;5:245-248.
39. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-923.
40. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part I: ethical and scientific issues. Ann Intern Med 2000;133:455-463.
41. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004;63:1779-1787.
42. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003;361:545-552.
43. Pohl D, Waubant E, Banwell B, et al. Treatment of pediatric multiple sclerosis and variants. Neurology 2007;68(suppl 2):S54-S65.
44. Barfield RC, Church C. Informed consent in pediatric clinical trials. Curr Opin Pediatr 2005;17:20-24.
45. Flotte TR, Frentzen B, Humphries MR, Rosenbloom AL. Recent developments in the protection of pediatric research subjects. J Pediatr 2006;149:285-286.